These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 354890

  • 21. [Volumetric correction of the maximal expiratory flow 25-75% in chronic obstructive bronchopneumopathies].
    Dull WL, Alexander MR, Kasik JE.
    Rev Fr Mal Respir; 1982; 10(5):337-44. PubMed ID: 7178638
    [Abstract] [Full Text] [Related]

  • 22. Clinical study on carbuterol (SKF 40383), a new selective bronchodilator agent aerosol: double blind comparison with isoproterenol aerosol.
    Saleeby PR, Ziskind MM.
    Curr Ther Res Clin Exp; 1975 Mar; 17(3):225-33. PubMed ID: 805017
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Response of patients with chronic obstructive lung disease to the regular administration of nebulized isoproterenol. A double-blind crossover study.
    Light RW, Summer WR, Luchsinger PC.
    Chest; 1975 Jun; 67(6):634-9. PubMed ID: 1092531
    [Abstract] [Full Text] [Related]

  • 25. Should the FVC be considered in evaluating response to bronchodilator?
    Girard WM, Light RW.
    Chest; 1983 Jul; 84(1):87-9. PubMed ID: 6861550
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Action of isoprenaline on the mechanical properties of lungs and airways in healthy people and patients with obstructive lung diseases.
    Bobbaers H, Stanescu DC, Demedts SM, Clément J, Pardaens J, van de Woestijne KP.
    Bull Eur Physiopathol Respir; 1976 Jul; 12(4):515-31. PubMed ID: 1087891
    [Abstract] [Full Text] [Related]

  • 31. Pulmonary-function testing in the evaluation of bronchodilator agents.
    Menendez R, Kelly HW.
    Clin Pharm; 1983 Jul; 2(2):120-8. PubMed ID: 6349904
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Bitolterol compared to isoproterenol in advanced chronic obstructive pulmonary disease.
    Petty TL, Scoggin CH, Rollins DR, Repsher LH.
    Chest; 1984 Sep; 86(3):404-8. PubMed ID: 6380974
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Bronchodilatory properties of 2-decarboxy-2-hydroxymethyl prostaglandin E1.
    Nizankowska E, Sheridan AQ, Maile MH, Cross CJ, Nizankowski R, Prochowska K, Szczeklik A.
    Prostaglandins; 1985 Mar; 29(3):349-62. PubMed ID: 3858912
    [Abstract] [Full Text] [Related]

  • 38. Long-term study comparing fenoterol and isoproterenol inhalation in asthmatic patients.
    Brandon ML.
    Ann Allergy; 1978 Feb; 40(2):86-93. PubMed ID: 343660
    [Abstract] [Full Text] [Related]

  • 39. Bronchodilatation and the inspiratory flow volume curve.
    Reddy R, Cook T, Tenholder MF.
    Chest; 1996 Nov; 110(5):1226-8. PubMed ID: 8915225
    [Abstract] [Full Text] [Related]

  • 40. The effect of tiotropium on the pulmonary diffusing capacity.
    Gonlugur U.
    Methods Find Exp Clin Pharmacol; 2007 Oct; 29(8):535-7. PubMed ID: 18040529
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.